EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce
  
From the very beginning, rare disease manufacturers need to consider EU-level joint clinical assessment data requirements when designing development programs . (Shutterstock)

More from Pink Sheet

More from Legislation